EGFR and leukoencephalopathy with calcifications and cysts: At present, the international discussion on the EGFR-targeting drug cetuximab reveals that most scholars believe that EGFR monoclonal antibody is more therapeutic for the overall survival of patients with LCC and could be used as a first-line optimized treatment for LCC.